Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Blood Neoplasia · 2026 · PMC12969294 · PMID 41808730

Europe PMC DOI

hedged sentences

0.0535

closest p · 1.1× alpha

0.0535

boldest claim

The sentences

showed a trendP = .0535so close (0.05 < p ≤ 0.1)

Primary disease showed a trend toward a superior response to GARD when compared with systemic disease (median survival, 10 years vs 11.5 years; P = .0535; supplemental Table 3 ; supplemental Figure 1 A).

also in 53,322 other papers

a strong trendno p-value reported

However, GARD showed a strong trend toward improved outcomes with the added advantage of offering a standardized treatment option with low toxicity for EBV+CNSL.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.